Technology readiness is not venture readiness

Technology readiness levels were designed to describe the maturity of a technology, not the viability of a business built on it. Yet in deep-tech and research-driven ventures, TRL is routinely used as a proxy for progress in board meetings, grant applications and investment memos.

The substitution is convenient and misleading. A venture at TRL 7 with no identified payer, no regulatory pathway and no freedom to operate is not de-risked; it is expensively committed. Meanwhile a venture at TRL 4 with a signed clinical partner, a clear reimbursement route and a defensible IP position may be materially more investable.

This is why the operating system scores ten dimensions rather than one. Solution and technology is one of them. Problem and need, customer and market, evidence and validation, business model, IP and defensibility, regulatory and compliance, team and execution, funding and capital, and risk and constraints are the others. Readiness is the weighted picture across all ten, weighted by sector — regulatory pathway carries far more weight in medtech than in software.

The practical consequence is that progress must be argued dimension by dimension, with evidence attached. "We advanced from TRL 6 to TRL 7" is a technical statement. "We moved evidence and validation from indicative to validated by completing the pilot with the paying customer" is a strategic one.